Vaxart Inc (VXRT)

$0.40 +0.04 (11.31%)
Market Cap 78.44M
Revenue (ttm) 28.70M
Net Income (ttm) -66.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233.28%
Debt to Equity Ratio 0.00
Volume 2,114,300
Avg Vol 1,961,302
Day's Range N/A - N/A
Shares Out 228.21M
Stochastic %K 79%
Beta 1.57
Analysts Strong Sell
Price Target $4.67

Latest News on VXRT

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 9 days ago

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 9 days ago

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 27, 2025, 8:00 AM EDT - 4 weeks ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 6:25 PM EDT - 5 weeks ago

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Mar 20, 2025, 4:01 PM EDT - 5 weeks ago

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Mar 11, 2025, 8:00 AM EDT - 6 weeks ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Mar 5, 2025, 4:05 PM EST - 7 weeks ago

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Jan 13, 2025, 7:55 PM EST - 3 months ago

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Dec 2, 2024, 4:01 PM EST - 5 months ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:19 PM EST - 5 months ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:01 PM EST - 5 months ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Sep 30, 2024, 4:12 PM EDT - 7 months ago

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Aug 15, 2024, 1:57 PM EDT - 9 months ago

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:51 PM EDT - 9 months ago

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 9 months ago

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Aug 2, 2024, 8:00 AM EDT - 9 months ago

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding

Jun 27, 2024, 8:00 AM EDT - 10 months ago

Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding

Vaxart Provides Business Update

Jun 17, 2024, 4:05 PM EDT - 11 months ago

Vaxart Provides Business Update

Vaxart Announces $40 Million Underwritten Offering of Common Stock

Jun 13, 2024, 7:07 PM EDT - 11 months ago

Vaxart Announces $40 Million Underwritten Offering of Common Stock

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Jun 13, 2024, 4:15 PM EDT - 11 months ago

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript

May 13, 2024, 5:49 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 7:03 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Mar 14, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Mar 7, 2024, 8:00 AM EST - 1 year ago

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Mar 6, 2024, 8:00 AM EST - 1 year ago

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Feb 5, 2024, 8:00 AM EST - 1 year ago

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Jan 19, 2024, 8:30 AM EST - 1 year ago

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Jan 16, 2024, 9:25 AM EST - 1 year ago

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Vaxart, Inc. Announces Management Change

Jan 16, 2024, 9:22 AM EST - 1 year ago

Vaxart, Inc. Announces Management Change

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Dec 21, 2023, 8:00 AM EST - 1 year ago

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 7:37 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 7:40 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

Jun 26, 2023, 4:45 PM EDT - 1 year ago

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

Jun 21, 2023, 4:30 PM EDT - 2 years ago

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

Jun 7, 2023, 9:16 AM EDT - 2 years ago

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

Jun 6, 2023, 4:01 PM EDT - 2 years ago

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

Vaxart, Inc. (VXRT) Q1 2023 Earnings Call Transcript

May 4, 2023, 6:10 PM EDT - 2 years ago

Vaxart, Inc. (VXRT) Q1 2023 Earnings Call Transcript

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results

May 4, 2023, 4:01 PM EDT - 2 years ago

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript

Mar 15, 2023, 8:51 PM EDT - 2 years ago

Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript

Vaxart Provides Business Update and Full Year 2022 Financial Results

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Vaxart Provides Business Update and Full Year 2022 Financial Results

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Mar 8, 2023, 4:05 PM EST - 2 years ago

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Vaxart Names Phillip Lee as Chief Financial Officer

Dec 19, 2022, 8:00 AM EST - 2 years ago

Vaxart Names Phillip Lee as Chief Financial Officer

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

Nov 22, 2022, 8:30 AM EST - 2 years ago

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29